Abstract

Advances in anti-inflammatory activity have opened the way for similar brakthroughs to be made in the fields of neuroprotection and remyelination.

This talk will examine these areas from the standpoint of trial design, particularly from the unmet needs of progressive disease.

A review of the characteristics of major outcome measures which are and/or maybe of value to measure these elements in terms of current understanding of the pathology.

A variety of outcome mesures and trial design elements will be discussed. For example MRI, OCT and Neurofilaments. They will be placed in context of current and recent clinical trials.

Human trials in neuroprotection and recently remyelination have started to report and a number of lessons are being learnt. Whilst many are at the early/mid-phase there are encouraging signs as the trial process continues to be refined.